M&A - RELMADA THERAPEUTICS, INC.

Form Type: 10-K

Filing Date: 2025-03-27

Corporate Action: Acquisition

Type: New

Accession Number: 000101376225003426

Filing Summary: Relmada Therapeutics, Inc., a clinical-stage biotechnology company, underwent significant strategic changes following disappointing interim analysis results regarding its lead product candidate, esmethadone, aimed at treating Major Depressive Disorder. Following this setback, the company shifted focus to acquiring new development candidates, leading to the licensing of NDV-01, a treatment for non-muscle-invasive bladder cancer, and the acquisition of Sepranolone, a neurosteroid for various applications including Prader-Willi syndrome and Tourette syndrome. The company has also paused its esmethadone program and the psilocybin project to concentrate resources on these new candidates. Financially, the report indicates significant losses for the prior two years and highlights the absence of revenue generation with a strategy focused on leveraging development expertise, diversifying its pipeline, and prioritizing late-stage programs.

Document Link: View Document

Form Type: 8-K

Filing Date: 2025-02-06

Corporate Action: Acquisition

Type: New

Accession Number: 000121390025010711

Filing Summary: On February 3, 2025, Relmada Therapeutics, Inc. entered into an Asset Purchase Agreement with Asarina Pharma AB to acquire Sepranolone, a phase 2b ready neurosteroid for treating Tourette Syndrome and other compulsive disorders, for €3,000,000. The payment structure includes €2,756,000 payable within ten business days after the agreement's effective date, with a credit of $250,000 for a previous payment. The agreement stipulates that Relmada will only assume liabilities arising after the effective date, and all prior liabilities will remain with Asarina. The agreement includes customary indemnification rights and various representations about the deal. The clinical data revealed that Sepranolone significantly reduced tic severity and improved quality of life in a Phase 2a study. Positive results were observed across multiple secondary endpoints, with a notable 28% reduction in tic severity without CNS side effects. A press release was issued on February 6, 2025, announcing the acquisition.

Document Link: View Document